Overcoming disease-specific matrix effect in a clinical pharmacokinetic assay using a microfluidic immunoassay technology.
Bioanalysis
; 9(16): 1207-1216, 2017 Aug.
Article
en En
| MEDLINE
| ID: mdl-28766364
ABSTRACT
AIM:
Etrolizumab, a humanized monoclonal antibody, has demonstrated clinical remission in a Phase II study of ulcerative colitis patients. In the Phase III program, a second indication, Crohn's disease was added. The pharmacokinetic ELISA used in the Phase I/II studies in normal human and ulcerative colitis sera exhibited matrix interference in the Crohn's disease population, necessitating implementation of a new technology. Methodology &results:
Optimization of the original ELISA and assay redevelopment using different antibody pairs did not result in substantive improvements, necessitating implementation of an alternative technology for assay development.CONCLUSION:
We highlight the challenges encountered with optimization/redevelopment of the original ELISA and discuss results of the new assay on the Gyros platform.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Ensayo de Inmunoadsorción Enzimática
/
Inmunoensayo
/
Enfermedad de Crohn
/
Dispositivos Laboratorio en un Chip
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Bioanalysis
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos